On September 16, GENSCRIPT BIO rose 3.4% in regular trading, trading at HK$33.38 per share, with turnover of HK$91.45 million. The rebound follows the completion of the company's share placement, with short-term dilution pressure now largely digested.

On September 15, GENSCRIPT BIO completed the delivery of 77,126,000 new shares at a placement price of HK$30.50 per share, representing approximately 3.50% of the pre-placement issued share capital. The placement, arranged by Citigroup and J.P. Morgan, raised gross proceeds of approximately HK$2.352 billion, with net proceeds of approximately HK$2.327 billion after deducting commissions and related expenses. The shares were placed to no fewer than six placees, and no placee became a substantial shareholder post-placement. On the prior trading day, the stock had declined 3.88% as the placement delivery day triggered dilution concerns and the placement price exerted downward pressure on the market price. With the placement now settled and the overhang cleared, the stock posted a recovery rally.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)